NES Healthcare UK

neshealthcare.co.uk

NES Healthcare has been established for over 25 years. We are the UK’s largest provider of Medical Officers to the Independent Healthcare Sector (private hospitals). We employ over 200 doctors from all over the world, and we currently work with over 100 hospitals and clinics to provide the highest level of patient care. In addition to the Resident Medical Officer (RMO) position, we offer a number of Specialist positions which offer good salaries and opportunities for a better work/life balance.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

SUONO BIO, INC. ANNOUNCES FORMULATION-AGNOSTIC PLATFORM FOR THE DELIVERY OF RNA THERAPEUTICS

Suono Bio | January 06, 2022

news image

Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, announced its latest publication in the Journal of Pharmaceutical Sciences demonstrating the capability to deliver unformulated RNA therapeutics against relevant disease targets in the gastrointestinal tract. This latest publication adds to the validation of Suono Bio’s therapeutic delivery platform leveraging low-frequency ultrasound for formulation-agnostic delivery. This technology wa...

Read More

Industrial Impact

EMPATICA RECEIVES NEW FDA CLEARANCE FOR ITS HEALTH MONITORING PLATFORM AND ANNOUNCES SERIES B FINANCING

Empatica | November 23, 2022

news image

Empatica, a digital health and AI company developing medical-grade wearables and algorithms for health monitoring and diagnostics, today announced the clearance of its Empatica Health Monitoring Platform by the U.S. Food and Drug Administration. The Empatica Health Monitoring Platform is a full-stack remote health monitoring and data collection solution for research and healthcare professionals, built on data collected by Empatica's medical-grade, CE-certified EmbracePlus wear...

Read More

Research

BIGHAT BIOSCIENCES COMPLETES FIRST STAGE OF RESEARCH COLLABORATION WITH AMGEN

BigHat Biosciences, Inc. | January 12, 2022

news image

BigHat Biosciences, Inc., a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, announced the successful completion of the first stage of a previously undisclosed research collaboration and licensing agreement with Amgen applying BigHat’s platform for multi-objective optimization of a next-generation antibody. BigHat’s antibody design platform integrates a high-speed characterization with AI/ML tech...

Read More

Industrial Impact

LINKINVAX AND INSERM TRANSFERT ENTER INTO AN EXCLUSIVE WORLDWIDE LICENSING AGREEMENT COVERING USE OF AN INNOVATIVE VACCINE PLATFORM

LinKinVax technology | February 04, 2022

news image

LinKinVax, a clinical-stage biotech company, is announcing the signing of an exclusive worldwide licensing agreement with Inserm Transfert to develop a vaccine strategy with an innovative mechanism of action. LinKinVax is developing a vaccine platform that directly targets dendritic cells.These cells play a crucial role in the immune system, stimulating and regulating immune responses. The agreement with Inserm Transfert covers industrial and commercial use, and the...

Read More
news image

Medical

SUONO BIO, INC. ANNOUNCES FORMULATION-AGNOSTIC PLATFORM FOR THE DELIVERY OF RNA THERAPEUTICS

Suono Bio | January 06, 2022

Suono Bio, Inc., the company revolutionizing the treatment of gastrointestinal diseases, announced its latest publication in the Journal of Pharmaceutical Sciences demonstrating the capability to deliver unformulated RNA therapeutics against relevant disease targets in the gastrointestinal tract. This latest publication adds to the validation of Suono Bio’s therapeutic delivery platform leveraging low-frequency ultrasound for formulation-agnostic delivery. This technology wa...

Read More
news image

Industrial Impact

EMPATICA RECEIVES NEW FDA CLEARANCE FOR ITS HEALTH MONITORING PLATFORM AND ANNOUNCES SERIES B FINANCING

Empatica | November 23, 2022

Empatica, a digital health and AI company developing medical-grade wearables and algorithms for health monitoring and diagnostics, today announced the clearance of its Empatica Health Monitoring Platform by the U.S. Food and Drug Administration. The Empatica Health Monitoring Platform is a full-stack remote health monitoring and data collection solution for research and healthcare professionals, built on data collected by Empatica's medical-grade, CE-certified EmbracePlus wear...

Read More
news image

Research

BIGHAT BIOSCIENCES COMPLETES FIRST STAGE OF RESEARCH COLLABORATION WITH AMGEN

BigHat Biosciences, Inc. | January 12, 2022

BigHat Biosciences, Inc., a biotechnology company with an artificial intelligence/machine learning-guided antibody discovery and development platform, announced the successful completion of the first stage of a previously undisclosed research collaboration and licensing agreement with Amgen applying BigHat’s platform for multi-objective optimization of a next-generation antibody. BigHat’s antibody design platform integrates a high-speed characterization with AI/ML tech...

Read More
news image

Industrial Impact

LINKINVAX AND INSERM TRANSFERT ENTER INTO AN EXCLUSIVE WORLDWIDE LICENSING AGREEMENT COVERING USE OF AN INNOVATIVE VACCINE PLATFORM

LinKinVax technology | February 04, 2022

LinKinVax, a clinical-stage biotech company, is announcing the signing of an exclusive worldwide licensing agreement with Inserm Transfert to develop a vaccine strategy with an innovative mechanism of action. LinKinVax is developing a vaccine platform that directly targets dendritic cells.These cells play a crucial role in the immune system, stimulating and regulating immune responses. The agreement with Inserm Transfert covers industrial and commercial use, and the...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us